Libtayo (cemiplimab)

Numéro de dossier de l’AMC: 21898
État des négociations:
Négociation conclue avoir atteint une entente
Indication(s):
Non-small cell lung cancer (NSCLC) expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
Promoteur/fabricant:
Sanofi-Aventis Canada Inc.
Numéro de projet de l’AMC:
PC0262
Lettre-contrat de l’APP:
Conclusion du processus de négociation: